Our in silico analyses indicate that high levels of Gpr125 are associated with particularly poor survival within basal breast cancer, a subtype with a great unmet need for markers that can parse the 30% of patients that relapse and die within two years from the 70% with more indolent tumors. This evidence concerns the gene ADGRA3 and breast cancer.